Loading...
•
Sep 30, 2023
Teva Q3 2023 Earnings Report
Teva delivered strong financial and business results with revenues increasing by 7% and increased revenue guidance.
Key Takeaways
Teva's Q3 2023 results showed a 7% increase in revenues to $3.9 billion, driven by the continued growth of AUSTEDO, AJOVY, and the global generics business. The company has raised its revenue outlook for 2023 for the second consecutive quarter.
Global revenues reached $3.9 billion, a 7% increase from Q3 2022, fueled by AUSTEDO, AJOVY, and global generics.
GAAP diluted EPS was $0.07, while non-GAAP diluted EPS was $0.60.
Cash flow from operating activities was $5 million, and free cash flow amounted to $229 million.
The company entered an exclusive collaboration with Sanofi on Anti TL1-A (TEV-‘574) in October 2023.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Teva revised 2023 revenues outlook to $15.1 - $15.5 billion from $15.0 - $15.4 billion and reaffirmed all other key components.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...